Jump to content

Search the Community

Showing results for tags 'sinovac'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Categories

  • Articles
    • Forum Integration
    • Frontpage
  • Pages
  • Miscellaneous
    • Databases
    • Templates
    • Media

Forums

  • Cars
    • General Car Discussion
    • Tips and Resources
  • Aftermarket
    • Accessories
    • Performance and Tuning
    • Cosmetics
    • Maintenance & Repairs
    • Detailing
    • Tyres and Rims
    • In-Car-Entertainment
  • Car Brands
    • Japanese Talk
    • Conti Talk
    • Korean Talk
    • American Talk
    • Malaysian Talk
    • China Talk
  • General
    • Electric Cars
    • Motorsports
    • Meetups
    • Complaints
  • Sponsors
  • Non-Car Related
    • Lite & EZ
    • Makan Corner
    • Travel & Road Trips
    • Football Channel
    • Property Buzz
    • Investment & Financial Matters
  • MCF Forum Related
    • Official Announcements
    • Feedback & Suggestions
    • FAQ & Help
    • Testing

Blogs

  • MyAutoBlog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Found 5 results

  1. Good news for the world. But pfizer and moderna are disappointing. mRNA supposed to be fast to develop, but now Apr, apparently still nothing, although they promised omicron-specific vaccine in Mar. Omicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial BEIJING, April 16 (Reuters) - COVID-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech (SVA.O) to target the Omicron variant were approved for clinical trials in Hong Kong, the companies said on Saturday. Scientists worldwide are racing to study upgraded injections against Omicron, as data indicated that antibodies elicited by vaccines based on older strains show weaker activity to neutralise the highly transmissible variant. The two candidates from units of Sinopharm subsidiary China National Biotec Group (CNBG) and one from Sinovac contain inactivated or "killed" coronavirus and are similar to vaccines that the companies are supplying in China and overseas, the companies said in statements. The Sinopharm candidates will be tested as boosters in adults who have already received two or three vaccine doses, CNBG said. It did not specify which vaccine products the trial participants would have received before taking the experimental booster, or how many subjects would be recruited. Sinovac said it will push forward studies in its existing CoronaVac vaccine's protection against emerging variants. A Chinese study showed that a fourth dose of BBIBP-CorV, an existing Sinopharm COVID vaccine, did not significantly lift antibody levels against Omicron when administered six months after a third booster dose to a regular two-dose regimen. While the fourth dose restored antibody levels to around the peaks that followed the third dose, researchers said new vaccines would offer a better alternative as future boosters. Reporting by Roxanne Liu and Andrew Galbraith; Editing by Edmund Klamann and William Mallard
  2. The Pfizer vaccine showed efficacy of 95% The Moderna vaccine was 94.1% Sinovac is 50.4%, dafug! https://asia.nikkei.com/Spotlight/Coronavirus/Sinovac-vaccine-disappoints-at-50.4-efficacy-latest-Brazil-data Sinovac vaccine disappoints at 50.4% efficacy: latest Brazil data Results come as scientists slam biomed center for raising 'unrealistic' hopes The Butantan biomedical production center in Sao Paulo, Brazil, is being blasted by scientists and observers for releasing partial data only days ago that generated unrealistic expectations. © Reuters January 13, 2021 10:34 JST SAO PAULO (Reuters) -- A coronavirus vaccine developed by China's Sinovac Biotech was just 50.4% effective at preventing symptomatic infections in a Brazilian trial, researchers said on Tuesday, barely enough for regulatory approval and well below the rate announced last week. The latest results are a major disappointment for Brazil, as the Chinese vaccine is one of two that the federal government has lined up to begin immunization during the second wave of the world's second-deadliest COVID-19 outbreak. Several scientists and observers blasted the Butantan biomedical center for releasing partial data just days ago that generated unrealistic expectations. The confusion may add to skepticism in Brazil about the Chinese vaccine, which President Jair Bolsonaro has criticized, questioning its "origins." "We have a good vaccine. Not the best vaccine in the world. Not the ideal vaccine," said microbiologist Natalia Pasternak, criticizing Butantan's triumphant tone. Last week, the Brazilian researchers had celebrated results showing 78% efficacy against "mild-to-severe" COVID-19 cases, a rate they later described as "clinical efficacy." They said nothing at the time about another group of "very mild" infections among those who received the vaccine that did not require clinical assistance. Ricardo Palacios, medical director for clinical research at Butantan, said on Tuesday that the new lower efficacy finding included data on those "very mild" cases. "We need better communicators," said Gonzalo Vecina Neto, a professor of public health at the University of Sao Paulo and former head of Brazilian health regulator Anvisa. Piecemeal disclosures about Chinese vaccine trials globally have raised concerns that they are not subject to the same public scrutiny as U.S. and European alternatives. Palacios and officials in the Sao Paulo state government, which funds Butantan, emphasized the good news that none of the volunteers inoculated with CoronaVac had to be hospitalized with COVID-19 symptoms. Public health experts said that alone will be a relief for Brazilian hospitals that are buckling under the strain of surging case loads. However, it will take longer to curb the pandemic with a vaccine that allows so many mild cases. "It's a vaccine that will start the process of overcoming the pandemic," Pasternak said. Researchers at Butantan delayed announcement of their results three times, blaming a confidentiality clause in a contract with Sinovac. In the meantime, Turkish researchers said last month that CoronaVac was 91.25% effective based on an interim analysis. Indonesia gave the vaccine emergency use approval on Monday based on interim data showing it is 65% effective. Butantan officials said the design of the Brazilian study, focusing on frontline health workers during a severe outbreak in Brazil and including elderly volunteers, made it impossible to compare the results directly with other trials or vaccines. Still, COVID-19 vaccines in use from Pfizer Inc with partner BioNTech SE and Moderna Inc proved to be about 95% effective in preventing illness in their pivotal late-state trials. The disappointing CoronaVac data is the latest setback for vaccination efforts in Brazil, where more than 200,000 people have died since the outbreak began - the worst death toll outside the United States. Brazil's national immunization program currently relies on CoronaVac and the vaccine developed by Oxford University and AstraZeneca Plc - neither of which has received regulatory approval in Brazil. Anvisa, which has stipulated an efficacy rate of at least 50% for vaccines in the pandemic, has already pressed Butantan for more details of its study, after it filed for emergency use authorization on Friday. The regulator said it will meet on Sunday to decide on emergency use requests for CoronaVac and the British vaccine. AstraZeneca failed to deliver active ingredients to Brazil over the weekend, leaving the government scrambling to import finished doses of the vaccine from India to begin inoculations.
  3. Sinovac lai liao. I guess HSA will fast track approve them for use, no point keeping them in cold storage space. Just in in time for the general population starting in April. Keeping finger crossed not to get it. https://www.moh.gov.sg/news-highlights/details/1-new-case-of-locally-transmitted-covid-19-infection-24-Feb-2021-Updated
  4. BioNTech vaccine creates 10 times more antibodies than Sinovac, study finds https://www.scmp.com/news/hong-kong/health-environment/article/3141285/coronavirus-hong-kong-biontech-vaccine-recipients "Though quantity of coronavirus-targeting proteins does not directly correlate to level of immunity, findings may suggest ‘substantial differences in vaccine effectiveness’ But study’s lead author notes moderate levels of protection are better than none at all, saying: ‘Don’t let the perfect be the enemy of the good’ ."
  5. https://asia.nikkei.com/Spotlight/Coronavirus/COVID-vaccines/Hundreds-of-Sinovac-injected-Indonesian-doctors-contract-COVID?utm_campaign=GL_coronavirus_latest&utm_medium=email&utm_source=NA_newsletter&utm_content=article_link&del_type=10&pub_date=20210618123000&seq_num=15&si=44594 Hundreds of Sinovac-injected Indonesian doctors contract COVID Dozens hospitalized as concerns rise over efficacy against more virulent strains A medical worker prepares a dose of the Sinovac vaccine before giving it to a doctor at a facility in Jakarta, Indonesia, on January 19, 2021. © Reuters June 17, 2021 17:36 JST JAKARTA (Reuters) -- More than 350 Indonesian doctors have contracted COVID-19 despite being vaccinated with Sinovac, and dozens have been hospitalized, officials said, as concerns rise about the efficacy of some vaccines against more virulent virus strains. Most of the doctors were asymptomatic and self-isolating at home, said Badai Ismoyo, head of the Kudus district health office in Central Java, but dozens were in hospital with high fevers and declining oxygen saturation levels. Kudus is battling an outbreak believed to be driven by the more transmissible Delta variant which has pushed bed occupancy rates above 90% in the district. Designated as a priority group, Indonesian health care workers were among the first to be vaccinated when the inoculation drive started in January. Almost all have received the COVID-19 vaccine developed by Chinese biopharmaceutical company Sinovac, according to the Indonesian Medical Association (IDI). While the number of Indonesian health care workers dying from COVID-19 has decreased significantly -- dropping from 158 deaths this January to 13 this May, according to data initiative group LaporCOVID-19 -- public health experts say the Java hospitalizations are cause for concern. "The data shows they have the Delta variant [in Kudus] so it is no surprise that the breakthrough infection is higher than before because as we know the majority of health care workers in Indonesia got Sinovac, and we still don't know yet how effective it is in the real world against the Delta variant," said Dicky Budiman, an epidemiologist from Australia's Griffith University. A spokesperson from Sinovac and Indonesia's ministry of health were not immediately available for comment on the efficacy of Sinovac's CoronaVac against newer coronavirus variants. Grappling with one of the worst outbreaks in Asia, with more than 1.9 million cases and 53,000 deaths, there has been a heavy toll on Indonesia's doctors and nurses with 946 deaths. Many are now experiencing pandemic fatigue and taking an increasingly laissez-faire approach to health protocols after being vaccinated, said Lenny Ekawati, from LaporCOVID-19. "That phenomenon happens quite often these days, not only within the community but also health care workers," she said, "They think because they are vaccinated that they are safe." But as more cases of the highly transmissible Delta variant are identified in the world's fourth most populous nation, the data is starting to tell a different story. Across Indonesia, at least five doctors and one nurse have died from COVID-19 despite being vaccinated, according to the data initiative group, although one had only received their first shot. In Kudus, one senior doctor has died, said IDI, although it is understood he had a comorbidity. In the Indonesian capital Jakarta, radiologist Dr Prijo Sidipratomo told Reuters he knew of at least half a dozen doctors in the city who had been hospitalized with COVID-19 in the past month despite being vaccinated, with one currently being treated in ICU. "It is alarming for us because we cannot rely on vaccinations only," he said, urging people to strictly adhere to health protocols. Weeks after the Muslim Eid Al-Fitr holidays, Indonesia has experienced a surge in cases, with the positivity rate exceeding 23% on Wednesday and daily cases nearing 10,000, the highest since late February. In its latest situation report the World Health Organization called for Indonesia to implement a stricter lockdown with increased transmission due to variants of concern and a "drastic increase in bed occupancy rates" necessitating urgent action.
×
×
  • Create New...